3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9
Leukemia
8
Leukemia, Myeloid, Chronic-Phase
7
Burkitt Lymphoma
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Prostatic Neoplasms
3
Multiple Myeloma
3
Lymphoma
3
Philadelphia Chromosome
2
Pancreatic Neoplasms
2
Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia, Biphenotypic, Acute
2
Hematologic Neoplasms
2
Glioma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostate Cancer Recurrent
1
Primary Myelofibrosis
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasm, Residual
1
Interventions
fludarabine
19
Whole-Body Irradiation
18
Cyclophosphamide
17
fludarabine phosphate
16
ruxolitinib
15
Mycophenolic Acid
14
Specimen Handling
13
Tacrolimus
11
Azacitidine
11
Biopsy
10
Peripheral Blood Stem Cell Transplantation
9
Melphalan
9
Cytarabine
9
venetoclax
8
Sirolimus
8
Busulfan
8
Stem Cell Transplantation
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Daunorubicin
5
Cyclosporine
5
CPX-351
5
luspatercept
4
ivosidenib
4
itacitinib
4
fedratinib
4
decitabine and cedazuridine drug combination
4
Thiotepa
4
Liposomes
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Dasatinib
×
1 year
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled